Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluating predictors of paclitaxel-associated peripheral neuropathy: a pharmacodynamic modelling approach

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: WILLIAMS OJARA, Francis (Freie Universitaet Berlin, Germany, Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Berlin, Germany)
  • Co-author(s): Francis Williams Ojara: Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Germany, Berlin, Germany
    Andrea Henrich: Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Germany, Berlin, Germany
    Markus Joerger : Medical Oncology and Hematology, Cantonal Hospital, St Gallen, Switzerland
    Charlotte Kloft : Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Germany, Berlin, Germany
  • Abstract:

    Backgrounds

    Peripheral neuropathy (PN) is a dose limiting, cumulative adverse event of paclitaxel (PTX) with relevant negative impact on patient’s quality of life (QoL). PTX dose and exposure (time above a threshold plasma concentration of 0.05 μM, TC>0.05) are known predictors of PN from standard statistical tests with a single severity grade per..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses